🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  2. TSB-9-W1

    Biotech Pharmaceutical Co.,

    Metastatic Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  3. TSC-204-A0201

    TScan Therapeutics

    Head and Neck Cancer

    phase 1 mab active

    1 trial

  4. TTI-101

    Tvardi Therapeutics

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  5. TTI-101

    Tvardi Therapeutics

    Breast Cancer

    phase 1 small molecule completed

    2 trials

  6. TTX-MC138-NODAGA-Cu64

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  7. TV46017

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease (COPD

    phase 1 small molecule terminated

    1 trial

  8. TV48108

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 1 small molecule terminated

    1 trial

  9. TYRA-300-B01

    Tyra Biosciences

    Healthy

    phase 1 small molecule active

    1 trial

  10. Tafamidis round 2, Tafamidis round 1, Tafamidis oblong

    Pfizer Australia Pty Ltd

    aransthyretin amyloid cardiomyopathy

    phase 1 small molecule active

    1 trial

  11. Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

    Disc Medicine

    Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma

    phase 1 other active

    1 trial

  12. Talampanel (non-radiolabeled), [14C] Talampanel

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule terminated

    1 trial

  13. Tasocitinib 10 mg oral tablet

    Pfizer

    Healthy

    phase 1 small molecule completed

    1 trial

  14. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  15. Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)

    S.L

    Healthy Adult Subjects

    phase 1 mab completed

    1 trial

  16. Tetrahydrobiopterin 10 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Claudication, Intermittent

    phase 1 small molecule active

    1 trial

  17. The 10mg dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

    Century Therapeutics

    systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]

    phase 1 other active

    1 trial

  19. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  20. The bioavailability study of Dapagliflozin

    Laboratorios Tillomed Spain S.L.U

    not applicable (submitted trial is a bioequivalence study

    phase 1 other active

    1 trial

  21. The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  22. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  23. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

    Sciencepharma Sp. z o.o

    Not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  24. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources